Plaintiff: Cadence Pharmaceuticals and SCR
Pharmatop
Defendant: Fresenius Kabi USA
Case Number:
3:13-cv-00139
Date Filed:
January 17, 2013
Court: California Southern District Court
Patents-in-Suit: US6028222 and US6992218
Patent Number
Current Assignee[i]
|
Issue
Date
|
Expiration
Date[ii]
|
Title
|
|
Feb 22, 2000
|
Aug 05, 2016
|
Stable liquid paracetamol
compositions, and method for preparing same
|
|
Jan 31, 2006
|
Jun 06, 2020
|
Method for obtaining aqueous
formulations of oxidation-sensitive active principles
|
Table Information
sourced from Maxval’s Assignment
Database.
For the above mentioned patents Cadence is the exclusive sub-licensee.
About the
Parties:
Cadence
Pharmaceuticals is a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally for
use in the hospital setting. Cadence currently markets Ofirmev, an intravenous
formulation of acetaminophen.
Fresenius Kabi is
focused on the care of critically and chronically ill patients inside and
outside the hospital. Its portfolio of products comprises a wide range of IV
drugs, infusion therapies, clinical nutrition products as well as the related
medical devices and blood transfusion technologies.
As in
Complaint:
Cadence is the current holder[iii]
with the New Drug Application (NDA) no. 022450 for Ofirmev®
(source: Maxval’s Patent
Marker), which was
approved by FDA.
Ofirmev is used to treat pain and to reduce fever. Ofirmev is sometimes given
with opioid (sometimes called narcotic) pain medication to treat moderate to
severe pain. Plaintiffs allege that defendant with the Abbreviated New Drug
Application (ANDA) no. 20-4767 seeks FDA approval to market a generic version
of Ofrimev that infringes the ‘222 and ‘218 patents.
Other Cases
Filed:
Cadence has filed another case (1:13-cv-00453) against Fresenius Kabi on January 18, 2013
which is pending.
If you are interested in knowing more about
the above case, please contact us.
To
get alerts on cases filed, subscribe to our Litigation
Alerts.
[i] MaxVal offers Patent Assignment Alert service where subscribers
receive email alerts when assignments relating to target applications, patents
or entities of interest are recorded.
[ii] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically
calculates patent terms and expiration dates for U.S. utility patents.
[iii] Patent Marker
provides an online environment where patentees can virtually mark products and
search for patent-related information.
No comments:
Post a Comment